Download PDF
Semin Respir Crit Care Med 2020; 41(05): 659-672
DOI: 10.1055/s-0040-1713615
Review Article

Sarcoidosis-Associated Pulmonary Hypertension

Marloes P. Huitema
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Harold Mathijssen
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Johannes J. Mager
2   Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Repke J. Snijder
2   Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Jan C. Grutters
2   Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands
3   Department of Pulmonology, University Medical Centre Utrecht, Utrecht, The Netherlands
,
Marco C. Post
1   Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands
4   Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Pulmonary hypertension (PH) is a well-known complication of sarcoidosis, defined by a mean pulmonary artery pressure of ≥25 mm Hg. Since both PH and sarcoidosis are rare diseases, data on sarcoidosis-associated PH (SAPH) is retrieved mostly from small retrospective studies. Estimated prevalence of SAPH ranges from 3% in patients referred to a tertiary center up to 79% in patients awaiting lung transplant. Most patients with SAPH show advanced parenchymal disease as the underlying mechanism. However, some patients have disproportional elevated pulmonary artery pressure, and PH can occur in sarcoidosis patients without parenchymal disease. Other mechanisms such as vascular disease, pulmonary embolisms, postcapillary PH, extrinsic compression, and other sarcoidosis-related comorbidities might contribute to SAPH. The diagnosis of PH in sarcoidosis is challenging since symptoms and signs overlap. Suspicion can be raised based on symptoms or tests, such as pulmonary function tests, laboratory findings, electrocardiography, or chest CT. PH screening mainly relies on transthoracic echocardiography. Right heart catheterization should be considered on a case-by-case basis in patients with clinical suspicion of PH, taking into account clinical consequences. Treatment options are considered on patient level in a PH expert center, and might include oxygen therapy, immunosuppressive, or PH-specific therapy. However, qualitative evidence is scarce. Furthermore, in a subset of patients, interventional therapy or eventually lung transplant can be considered. SAPH is associated with high morbidity. Mortality is higher in sarcoidosis patients with PH compared with those without PH, and increases in patients with more advanced stages of sarcoidosis and/or PH.

Keywords

pulmonary hypertension - sarcoidosis - sarcoidosis-associated pulmonary hypertension


Publication History

Article published online:
10 August 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Zimmerman I, Mann N. Boeck's sarcoid; a case of sarcoidosis complicated by pulmonary emphysema and cor pulmonale. Ann Intern Med 1949; 31 (01) 153-162
    CrossrefPubMedGoogle Scholar
  • 2 Galiè N, Humbert M, Vachiery J-L. , et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37 (01) 67-119
    CrossrefPubMedGoogle Scholar
  • 3 Hoeper MM, Bogaard HJ, Condliffe R. , et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (25, Suppl): D42-D50
    CrossrefPubMedGoogle Scholar
  • 4 Simonneau G, Montani D, Celermajer DS. , et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53 (01) 1801913
    CrossrefPubMedGoogle Scholar
  • 5 Caminati A, Cassandro R, Harari S. Pulmonary hypertension in chronic interstitial lung diseases. Eur Respir Rev 2013; 22 (129) 292-301
    CrossrefPubMedGoogle Scholar
  • 6 Handa T, Nagai S, Miki S. , et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129 (05) 1246-1252
    CrossrefPubMedGoogle Scholar
  • 7 Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32 (02) 296-302
    CrossrefPubMedGoogle Scholar
  • 8 Alhamad EH, Idrees MM, Alanezi MO, Alboukai AA, Shaik SA. Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in Arab patients. Ann Thorac Med 2010; 5 (02) 86-91
    CrossrefPubMedGoogle Scholar
  • 9 Huitema MP, Bakker ALM, Mager JJ. , et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. Eur Respir J 2019; 54 (04) 1900897
    CrossrefPubMedGoogle Scholar
  • 10 Tiosano S, Versini M, Dar Antaki L. , et al. The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension - a cohort study. Clin Immunol 2019; 199: 57-61
    CrossrefPubMedGoogle Scholar
  • 11 Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128 (03) 1483-1489
    CrossrefPubMedGoogle Scholar
  • 12 Shlobin OA, Kouranos V, Barnett SD. , et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J 2020; 55 (05) 1901747
    CrossrefPubMedGoogle Scholar
  • 13 Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138 (05) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 14 Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?. J Heart Lung Transplant 2008; 27 (03) 329-334
    CrossrefPubMedGoogle Scholar
  • 15 Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25 (05) 783-788
    CrossrefPubMedGoogle Scholar
  • 16 Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest 2015; 147 (02) 438-449
    CrossrefPubMedGoogle Scholar
  • 17 Boucly A, Cottin V, Nunes H. , et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J 2017; 50 (04) 1700465
    CrossrefPubMedGoogle Scholar
  • 18 Baughman RP, Shlobin OA, Wells AU. , et al. Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. Respir Med 2018; 139: 72-78
    CrossrefPubMedGoogle Scholar
  • 19 Nunes H, Humbert M, Capron F. , et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61 (01) 68-74
    CrossrefPubMedGoogle Scholar
  • 20 Keir GJ, Walsh SLF, Gatzoulis MA. , et al. Treatment of sarcoidosis-associated pulmonary hypertension: a single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffus Lung Dis 2014; 31 (02) 82-90
    PubMedGoogle Scholar
  • 21 Rapti A, Kouranos V, Gialafos E. , et al. Elevated pulmonary arterial systolic pressure in patients with sarcoidosis: prevalence and risk factors. Lung 2013; 191 (01) 61-67
    CrossrefPubMedGoogle Scholar
  • 22 Barnett CF, Bonura EJ, Nathan SD. , et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135 (06) 1455-1461
    CrossrefPubMedGoogle Scholar
  • 23 Maimon N, Salz L, Shershevsky Y, Matveychuk A, Guber A, Shitrit D. Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function. Int J Tuberc Lung Dis 2013; 17 (03) 406-411
    CrossrefPubMedGoogle Scholar
  • 24 Dickinson MG, Bartelds B, Borgdorff MAJ, Berger RMF. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol 2013; 305 (01) L1-L14
    CrossrefPubMedGoogle Scholar
  • 25 Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23 (11) 1216-1223
    CrossrefPubMedGoogle Scholar
  • 26 Lantuéjoul S, Sheppard MN, Corrin B, Burke MM, Nicholson AG. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006; 30 (07) 850-857
    CrossrefPubMedGoogle Scholar
  • 27 Jones RM, Dawson A, Jenkins GH, Nicholson AG, Hansell DM, Harrison NK. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J 2009; 34 (02) 517-520
    CrossrefPubMedGoogle Scholar
  • 28 Hoffstein V, Ranganathan N, Mullen JB. Sarcoidosis simulating pulmonary veno-occlusive disease. Am Rev Respir Dis 1986; 134 (04) 809-811
    PubMedGoogle Scholar
  • 29 Rubens C, Ewert R, Halank M. , et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120 (05) 1562-1569
    CrossrefPubMedGoogle Scholar
  • 30 Letizia C, Danese A, Reale MG. , et al. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med 2001; 43 (04) 257-261
    PubMedGoogle Scholar
  • 31 Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001; 179 (03) 163-174
    CrossrefPubMedGoogle Scholar
  • 32 Terashita K, Kato S, Sata M, Inoue S, Nakamura H, Tomoike H. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology 2006; 11 (02) 145-151
    CrossrefPubMedGoogle Scholar
  • 33 Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120 (03) 866-872
    CrossrefPubMedGoogle Scholar
  • 34 Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130 (05) 1481-1488
    CrossrefPubMedGoogle Scholar
  • 35 Sakao S, Tanabe N, Tatsumi K. Hypoxic pulmonary vasoconstriction and the diffusing capacity in pulmonary hypertension secondary to idiopathic pulmonary fibrosis. J Am Heart Assoc 2019; 8 (16) e013310
    CrossrefPubMedGoogle Scholar
  • 36 Swigris JJ, Olson AL, Huie TJ. , et al. Increased risk of pulmonary embolism among US decedents with sarcoidosis from 1988 to 2007. Chest 2011; 140 (05) 1261-1266
    CrossrefPubMedGoogle Scholar
  • 37 Vorselaars ADM, Snijder RJ, Grutters JC. Increased number of pulmonary embolisms in sarcoidosis patients. Chest 2012; 141 (03) 826-827
    CrossrefPubMedGoogle Scholar
  • 38 Crawshaw AP, Wotton CJ, Yeates DGR, Goldacre MJ, Ho LP. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax 2011; 66 (05) 447-448
    CrossrefPubMedGoogle Scholar
  • 39 Ungprasert P, Crowson CS, Matteson EL. Association of sarcoidosis with increased risk of VTE: a population-based study, 1976 to 2013. Chest 2017; 151 (02) 425-430
    CrossrefPubMedGoogle Scholar
  • 40 Goljan-Geremek A, Geremek M, Puscinska E, Sliwinski P. Venous thromboembolism and sarcoidosis: co-incidence or coexistence?. Cent Eur J Immunol 2015; 40 (04) 477-480
    CrossrefPubMedGoogle Scholar
  • 41 Nasher O, Boldy DA. Sarcoidosis: clinical mimicry of pulmonary embolism. BMJ Case Rep 2013; 2013: 1641-1641
    CrossrefPubMedGoogle Scholar
  • 42 Joyce E, Ninaber MK, Katsanos S. , et al. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 2015; 17 (01) 51-62
    CrossrefPubMedGoogle Scholar
  • 43 Guazzi M, Borlaug BA. Pulmonary hypertension due to left heart disease. Circulation 2012; 126 (08) 975-990
    CrossrefPubMedGoogle Scholar
  • 44 Birnie DH, Kandolin R, Nery PB, Kupari M. Cardiac manifestations of sarcoidosis: diagnosis and management. Eur Heart J 2017; 38 (35) 2663-2670
    PubMedGoogle Scholar
  • 45 Birnie D, Ha ACT, Gula LJ, Chakrabarti S, Beanlands RSB, Nery P. Cardiac sarcoidosis. Clin Chest Med 2015; 36 (04) 657-668
    CrossrefPubMedGoogle Scholar
  • 46 Ponikowski P, Voors AA, Anker SD. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27) 2129-2200
    CrossrefPubMedGoogle Scholar
  • 47 Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest 1980; 78 (06) 888-891
    CrossrefPubMedGoogle Scholar
  • 48 Seferian A, Steriade A, Jaïs X. , et al. Pulmonary hypertension complicating fibrosing mediastinitis. Medicine (Baltimore) 2015; 94 (44) e1800
    CrossrefPubMedGoogle Scholar
  • 49 Turner GA, Lower EE, Corser BC, Gunther KL, Baughman RP. Sleep apnea in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14 (01) 61-64
    PubMedGoogle Scholar
  • 50 Lal C, Medarov BI, Judson MA. Interrelationship between sleep-disordered breathing and sarcoidosis. Chest 2015; 148 (04) 1105-1114
    CrossrefPubMedGoogle Scholar
  • 51 Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 1996; 109 (02) 380-386
    CrossrefPubMedGoogle Scholar
  • 52 Sanner BM, Doberauer C, Konermann M, Sturm A, Zidek W. Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 1997; 157 (21) 2483-2487
    CrossrefPubMedGoogle Scholar
  • 53 Krieger J, Sforza E, Apprill M, Lampert E, Weitzenblum E, Ratomaharo J. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. Chest 1989; 96 (04) 729-737
    CrossrefPubMedGoogle Scholar
  • 54 Cremers J, Drent M, Driessen A. , et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol 2012; 24 (01) 17-24
    CrossrefPubMedGoogle Scholar
  • 55 Fetzer DT, Rees MA, Dasyam AK, Tublin ME. Hepatic sarcoidosis in patients presenting with liver dysfunction: imaging appearance, pathological correlation and disease evolution. Eur Radiol 2016; 26 (09) 3129-3137
    CrossrefPubMedGoogle Scholar
  • 56 Gupta S, Faughnan ME, Prud'homme GJ, Hwang DM, Munoz DG, Kopplin P. Sarcoidosis complicated by cirrhosis and hepatopulmonary syndrome. Can Respir J 2008; 15 (03) 124-126
    CrossrefPubMedGoogle Scholar
  • 57 Salazar A, Mañá J, Sala J, Landoni BR, Manresa F. Combined portal and pulmonary hypertension in sarcoidosis. Respiration 1994; 61 (02) 117-119
    CrossrefPubMedGoogle Scholar
  • 58 Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis 1988; 5 (01) 51-55
    PubMedGoogle Scholar
  • 59 Crouser ED, Maier LA, Wilson KC. , et al. Diagnosis and detection of sarcoidosis. An official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201 (08) e26-e51 [Internet]
    CrossrefPubMedGoogle Scholar
  • 60 Huitema MP, Spee M, Vorselaars VMM. , et al. Pulmonary artery diameter to predict pulmonary hypertension in pulmonary sarcoidosis. Eur Respir J 2016; 47 (02) 673-676
    CrossrefPubMedGoogle Scholar
  • 61 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166 (01) 111-117
    CrossrefPubMedGoogle Scholar
  • 62 Alhamad EH, Shaik SA, Idrees MM, Alanezi MO, Isnani AC. Outcome measures of the 6 minute walk test: relationships with physiologic and computed tomography findings in patients with sarcoidosis. BMC Pulm Med 2010; 10 (01) 42
    CrossrefPubMedGoogle Scholar
  • 63 Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132 (01) 207-213
    CrossrefPubMedGoogle Scholar
  • 64 Armstrong HF, Schulze PC, Bacchetta M, Thirapatarapong W, Bartels MN. Impact of pulmonary hypertension on exercise performance in patients with interstitial lung disease undergoing evaluation for lung transplantation. Respirology 2014; 19 (05) 675-682
    CrossrefPubMedGoogle Scholar
  • 65 Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. BMJ 1961; 2 (5261): 1165-1172
    CrossrefPubMedGoogle Scholar
  • 66 Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GB, Presberg KW. ; Medical College of Wisconsin Lung Transplant Group. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest 1998; 113 (05) 1250-1256
    CrossrefPubMedGoogle Scholar
  • 67 McCall RK, Ravenel JG, Nietert PJ, Granath A, Silver RM. Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis. J Comput Assist Tomogr 2014; 38 (02) 163-168
    CrossrefPubMedGoogle Scholar
  • 68 Alhamad EH, Al-Boukai AA, Al-Kassimi FA. , et al. Prediction of pulmonary hypertension in patients with or without interstitial lung disease: reliability of CT findings. Radiology 2011; 260 (03) 875-883
    CrossrefPubMedGoogle Scholar
  • 69 Zisman DA, Karlamangla AS, Ross DJ. , et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132 (03) 773-779
    CrossrefPubMedGoogle Scholar
  • 70 Devaraj A, Wells AU, Meister MG, Corte TJ, Hansell DM. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008; 249 (03) 1042-1049
    CrossrefPubMedGoogle Scholar
  • 71 Bonham CA, Oldham JM, Gomberg-Maitland M, Vij R. Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series. Chest 2015; 148 (04) 1055-1062
    CrossrefPubMedGoogle Scholar
  • 72 Handa T, Nagai S, Ueda S. , et al. Significance of plasma NT-proBNP levels as a biomarker in the assessment of cardiac involvement and pulmonary hypertension in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27 (01) 27-35
    PubMedGoogle Scholar
  • 73 Rudski LG, Lai WW, Afilalo J. , et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23 (07) 685-713 , quiz 786–788
    CrossrefPubMedGoogle Scholar
  • 74 Amsallem M, Sternbach JM, Adigopula S. , et al. Addressing the controversy of estimating pulmonary arterial pressure by echocardiography. J Am Soc Echocardiogr 2016; 29 (02) 93-102
    CrossrefPubMedGoogle Scholar
  • 75 Arcasoy SM, Christie JD, Ferrari VA. , et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167 (05) 735-740
    CrossrefPubMedGoogle Scholar
  • 76 Nathan SD. Pulmonary hypertension in interstitial lung disease. Int J Clin Pract Suppl 2008; 62 (160) 21-28
    CrossrefPubMedGoogle Scholar
  • 77 Amsallem M, Boulate D, Kooreman Z. , et al. Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease. Int J Cardiovasc Imaging 2017; 33 (06) 825-835
    CrossrefPubMedGoogle Scholar
  • 78 Huitema MP, Bakker ALM, Mager JJ. , et al. Predicting pulmonary hypertension in sarcoidosis; value of PH probability on echocardiography. Int J Cardiovasc Imaging 2020; DOI: 10.1007/s10554-020-01859-9.
    CrossrefPubMedGoogle Scholar
  • 79 Keir GJ, Wort SJ, Kokosi M. , et al. Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology 2018; 23 (07) 687-694
    CrossrefPubMedGoogle Scholar
  • 80 Hoeper MM, Lee SH, Voswinckel R. , et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48 (12) 2546-2552
    CrossrefPubMedGoogle Scholar
  • 81 Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3 (04) 403-407
    CrossrefPubMedGoogle Scholar
  • 82 Keijsers RGM, Grutters JC. In which patients with sarcoidosis is FDG PET/CT indicated?. J Clin Med 2020; 9 (03) 890
    CrossrefPubMedGoogle Scholar
  • 83 Baughman RP, Judson MA, Lower EE. , et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (02) 110-120
    PubMedGoogle Scholar
  • 84 Judson MA, Highland KB, Kwon S. , et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (02) 139-145
    PubMedGoogle Scholar
  • 85 Baughman RP, Culver DA, Cordova FC. , et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest 2014; 145 (04) 810-817
    CrossrefPubMedGoogle Scholar
  • 86 Mathijssen H, Huitema MP, Bakker A. , et al. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37 (01) 74-78
    PubMedGoogle Scholar
  • 87 Ford HJ, Baughman RP, Aris R, Engel P, Donohue JF. Tadalafil therapy for sarcoidosis-associated pulmonary hypertension. Pulm Circ 2016; 6 (04) 557-562
    CrossrefPubMedGoogle Scholar
  • 88 Dobarro D, Schreiber BE, Handler C, Beynon H, Denton CP, Coghlan JG. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol 2013; 111 (02) 278-285
    CrossrefPubMedGoogle Scholar
  • 89 Barst RJ, Ratner SJ. Sarcoidosis and reactive pulmonary hypertension. Arch Intern Med 1985; 145 (11) 2112-2114
    CrossrefPubMedGoogle Scholar
  • 90 Sitbon O, Channick R, Chin KM. , et al; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373 (26) 2522-2533
    CrossrefPubMedGoogle Scholar
  • 91 Galiè N, Barberà JA, Frost AE. , et al; AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373 (09) 834-844
    CrossrefPubMedGoogle Scholar
  • 92 Corte TJ, Wells AU, Nicholson AG, Hansell DM, Wort SJ. Pulmonary hypertension in sarcoidosis: a review. Respirology 2011; 16 (01) 69-77
    CrossrefPubMedGoogle Scholar
  • 93 Raghu G, Behr J, Brown KK. , et al; ARTEMIS-IPF Investigators*. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013; 158 (09) 641-649
    CrossrefPubMedGoogle Scholar
  • 94 Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113 (01) 237-240
    CrossrefPubMedGoogle Scholar
  • 95 Hamilton-Craig CR, Slaughter R, McNeil K, Kermeen F, Walters DL. Improvement after angioplasty and stenting of pulmonary arteries due to sarcoid mediastinal fibrosis. Heart Lung Circ 2009; 18 (03) 222-225
    CrossrefPubMedGoogle Scholar
  • 96 Condado JF, Babaliaros V, Henry TS, Kaebnick B, Kim D, Staton Jr GWJ. Pulmonary stenting for the treatment of sarcoid induced pulmonary vascular stenosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33 (03) 281-287
    PubMedGoogle Scholar
  • 97 Liu L, Xu J, Zhang Y. , et al. Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension. Clin Respir J 2017; 11 (06) 906-914
    CrossrefPubMedGoogle Scholar
  • 98 Yusen RD, Edwards LB, Kucheryavaya AY. , et al; International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33 (10) 1009-1024
    CrossrefPubMedGoogle Scholar
  • 99 Orens JB, Estenne M, Arcasoy S. , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (07) 745-755
    CrossrefPubMedGoogle Scholar
  • 100 Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124 (03) 922-928
    CrossrefPubMedGoogle Scholar
  • 101 Nardi A, Brillet P-Y, Letoumelin P. , et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38 (06) 1368-1373
    CrossrefPubMedGoogle Scholar
  • 102 Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest 2018; 153 (01) 105-113
    CrossrefPubMedGoogle Scholar